

32

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07810 A2

(51) International Patent Classification⁷: **A61M 25/00.**
5/142

Drive, Mounds View, MN 55112 (US). **HANKNER, Douglas, O.**; 1482 North Innsbruck, Fridley, MN 55432 (US). **HAMLEN, Robert, C.**; 6820 Woodale Avenue South, Edina, MN 55435 (US).

(21) International Application Number: PCT/US01/23434

(74) Agents: **WALDKOETTER, Eric, R.** et al.; Medtronic, Inc. LC340, 710 Medtronic Parkway, Minneapolis, MN 55432 (US).

(22) International Filing Date: 26 July 2001 (26.07.2001)

(74) Agents: **WALDKOETTER, Eric, R.** et al.; Medtronic, Inc. LC340, 710 Medtronic Parkway, Minneapolis, MN 55432 (US).

(25) Filing Language: English

(81) Designated States (national): AU, CA.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,

(30) Priority Data:
09/625,751 26 July 2000 (26.07.2000) US

CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicant: **MEDTRONIC, INC.** [US/US]: 710
Medtronic Parkway Northeast, Minneapolis, MN 55432
(US).

Published:

— without international search report and to be republished upon receipt of that report

(72) Inventors: **ELSBERRY, Dennis, D.**; 5345 Union Terrace Lane North, Plymouth, MN 55442 (US). **CHRISTIANSEN, Chris**; 4641 Hillvale Circle North, Oakdale, MN 55128 (US). **MORRIS, Mary, M.**; 2917 Woodale

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

WO 02/07810

(54) Title: CATHETER FOR TARGET SPECIFIC DRUG DELIVERY

(57) **Abstract:** A medical catheter comprising a proximal end having an opening for fluid containing a therapeutic drug, a distal end, the distal end defining at least one opening, and a porous portion covering the opening defined by the distal end. In one embodiment, the medical catheter comprises a proximal end having an opening for fluid containing a therapeutic drug, at least two distal ends, the proximal end connected to the two distal ends with a connector, the distal ends each defining at least one opening, a diffuser covering the opening of each distal end, and a separate restrictor downstream of the connector and upstream of each distal end to provide substantially equal flow through each distal end. An additional restrictor can also be placed upstream of the connector. In another embodiment, a combination diffuser and restrictor covers the opening of each distal end.

CATHETER FOR TARGET SPECIFIC DRUG DELIVERY

FIELD OF INVENTION

5 This invention relates to medical catheters for target specific drug delivery.

BACKGROUND OF THE INVENTION

Medical therapies may require the targeting of the therapy to a targeted patient site to maximize the therapeutic benefit and/or minimizing adverse effects to other organs or tissues outside the targeted patient site.

10 Huss & Reinhardt, U.S. Patent No. 4,968,306 describes an elongated catheter assembly for intravascular delivery of intravenous therapeutic fluids. This assembly has a distal end having multiple pores which is sheathed by an outer proximal segment for variable exposure of delivery surface area by sliding the distal segment from the outer proximal sheath. A disadvantage of this assembly is that it results in a lack of homogeneity of pore placement and pore number for fluid discharge, which indicates a pore size of 2-20 microns.

15 Delgado, U.S. Patent No. 3,640,269 describes a fluid delivery assembly having two flexible fluid-impermeable tubes open at one end and provided with an enlarged flexible permeable bag at the delivery segment. This bag is comprised of a membrane having uniform porosity less than 0.5 microns and having a water permeability of at least 60 mL/minute/cm as a description of fluid permeability. While this design is capable of uniform fluid delivery to tissues adjacent to the permeable bag, a disadvantage of this assembly is its inability to be specifically targeted to a patient site due to the flexible distal bag.

20 Thus, there is a need for a device that provides uniform distribution of therapeutic agents to a targeted patient site or multiple targets sites. There is also a need for a device that provides this uniform distribution, yet has sufficient rigidity for accurate placement of the device so that it can deliver therapeutic agents to the targeted patient site or multiple sites.

SUMMARY OF THE INVENTION

A new medical catheter has now been discovered that provides uniform distribution of therapeutic agents to a targeted patient site. Moreover, the medical catheter of the present

invention has a unique structure that permits it to be accurately placed so that it can uniformly distribute therapeutic agents to the targeted patient site.

In a one embodiment of the present invention, the catheter has at least two distal ends, and a proximal end joined to the two distal ends via a connector, such as a AY@ connector having three legs. Thus, the two distal ends and the proximal end are each located at a separate ends of the legs of the connector. Preferably, restrictors are placed in each leg of the connector. A restrictor is a structure that provides a significant pressure drop when fluid flows through that structure. The restrictors of the present invention provide structure to balance the flow for a multiple catheter system. The restrictors can be made of any suitable material, e.g. a powder material such as sintered metal powder. In this embodiment, diffusers are placed at the distal ends. A diffuser is a structure that diffuses and delivers a therapeutic agent over a large surface area as opposed to a single point source. In this embodiment, the diffusers and restrictors, which are in each leg having a distal end, are separated from each other. Preferably, the diffuser is at the tip of each distal end, and the each restrictor is upstream of the distal end. This construction is particularly useful for delivery of drugs via multiple catheter ends. For example, drug delivery to the two different hemispheres of the brain may be achieved, and the present invention can deliver drugs to each hemisphere substantially equally because of the restrictor(s) upstream of the distal ends, rather than at the distal ends as are the diffusers. In this embodiment of the present invention the following benefits are obtained by separating the diffuser and the restrictor: (1) increase in design options for the catheter tip; (2) improved reliability of catheter tip that is implanted in the brain tissue; and (3) reduced need to test the restrictor structure for biostability.

In another embodiment of the present invention, a restrictor is placed upstream of the Y connector as well, so that there is a restrictor in all three legs of the catheter joined by the Y connector. This construction provides additional benefits. For example, having the restrictor upstream of the Y connector acts as a pre-filter, and thus removes any particulates prior to the Y connector. This pre-filter function reduces particulates to the restrictors downstream of the Y connector, thus reducing the potential for different pressure drops and flow rates through the restrictors downstream of the Y connector, and ultimately the flow rate of the delivered drug through the diffusers at the distal ends. In addition, this embodiment eliminates the possibility for

insertion of a catheter where only one restrictor is downstream of the Y connector, and one restrictor is upstream of the Y connector.

In another embodiment, the catheter of the present invention comprises a rigid assembly having a rigid tube for positioning the distal end of the catheter near a targeted patient site or sites, the distal end of the catheter has a rigid porous delivery segment having a porosity less than 5 0.50 microns for achieving homogenous delivery to the targeted patient site. More specifically, in this embodiment, the catheter of the present invention has a rigid assembly having an open tube having a distal end, the distal end having sintered metal powder, for example, metal microspheres to provide uniform porosity of the delivery segment. In this embodiment, the distal end comprises at least one uniform surface made of sintered metal powder. Preferably, the 10 sintered metal powder can be made of any light-weight, high tensile strength material, e.g., tungsten, titanium or tantalum. In this embodiment, the rigid assembly functions as both a diffuser and a restrictor. The sintered metal rigid assembly of this embodiment can be fabricated using a single cavity carbon mold, and a mold insert. Alternatively, the sintered metal rigid 15 assembly can be fabricated using powdered metal and pyrogenic sintering, such as high pressure plus pyrogenic sintering. Sintered metal rigid assemblies can be positioned at the distal ends of separate legs of a catheter for placement at multiple patient targets. The distal ends can each join to a connector (e.g., a AY@ connector) for connection to a single therapy source. The sintered metal rigid assembly of this embodiment functions as both a fluid restrictor and a fluid diffuser. 20 Thus, the diffuser and restrictor functions can be combined, as in a membrane tip, or separated, with the restrictor being upstream of the diffuser in each leg of the catheter.

When it is desired for the sintered metal powder to be radiopaque, a radiopaque material can be used, such as tungsten, titanium or tantalum. These metals are non-magnetic, and therefore are safe within a magnetic imaging environment.

An objective of the present invention is to provide for multiple catheter ends for drug delivery arising from a single pump source. The present invention provides a catheter construction that provides desired distribution in a targeted area of the patient, such as giving medications intraparenchymally into tissue. Drug delivery by the present invention can be to an organ, and uniform distribution to that organ may be desired. It is a further objective of the 25

present invention to provide for multiple catheter ends, at least two, into the brain of patient, and more specifically, into the two different hemispheres of the brain, with each catheter end supplied with therapeutic drugs by the same pump, and with the fluid flow of the therapeutic agent being substantially equal between the two catheter ends. It is usually desirable to have equal amounts
5 of drug delivered to both brain hemispheres.

Another objective of the present invention is to provide a catheter to diffuse a therapeutic agent over a larger surface area than from a single point source. This structure results in a decrease in fluid flux and reduces potential for damaging tissue near the infusion site. In order for equal or near equal bilateral drug delivery to occur, two distal ends are required since fluid delivered from one distal end to a target site at one hemisphere will not deliver fluid to the other
10 hemisphere.
15

The present invention can be used for many drug delivery applications, including but not limited, to intraparenchymal or tissue infusion (such as brain tissue infusion), intrathecal drug delivery and intracerebral ventricular (ICV) drug delivery, or any drug infusion into a fluid filled space or to a tumor.
15

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates the catheter of the present invention, as implanted in a preferred location of the human body, and for drug delivery to each side of a patient=s brain.
20

Figure 2 is a top view of the catheter of the present invention as implanted and which provides drug delivery to the two hemispheres of a patient=s brain.
25

Figure 3A illustrates an embodiment of the catheter of the present invention in combination with device 20.

Figure 3B illustrates another embodiment of the catheter of the present invention in combination with device 20.
25

Figure 3C illustrates another embodiment of the catheter of the present invention in combination with device 20, this embodiment having two diffuser and restrictor distal catheter segments.

Figure 3D illustrates another embodiment of the present invention in combination with device 20, this embodiment having more than two diffuser and restrictor distal catheter segments.

Figure 4A illustrates another embodiment of the catheter of the present invention in combination with device 20, this embodiment having a separate restrictor placed between each diffuser distal catheter segment and connector 50.

Figure 4B illustrates another embodiment of the present invention in combination with device 20, this embodiment having multiple connectors 50, and multiple diffuser distal catheter segments with separate restrictors placed between each diffuser distal catheter segment and a corresponding connector 50.

Figure 5A illustrates another embodiment of the catheter of the present invention in combination with device 20, this embodiment having separate restrictors placed between each diffuser distal catheter segment and a corresponding connector 50, and a restrictor 90 placed between proximal end 24 and the first connector 50 downstream of proximal end 24.

Figure 5B shows the same structure as Figure 4B, except that in this other embodiment of the present invention, a restrictor 90 is placed between proximal end 24 and the first connector 50 downstream of proximal end 24.

Figure 6 is a cross section view of one embodiment of a diffuser of the present invention taken from its distal end, which illustrates openings that are tapered as they extend from the outside diameter of the diffuser to the inside diameter of the diffuser.

Figure 7 is the side view of one embodiment of the diffuser of the present invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

As shown in Figures 1 and 2, in an embodiment of the present invention, catheter 22 has a proximal end 24, and distal ends 26 and 26'. Distal ends 26 and 26' are connected to catheter 22, which splits at a AY@ connector 50. Distal end 26 is positioned in the right anterior cerebral cortex 16, and distal end 26' is positioned in the left anterior cerebral cortex 16'. Proximal end 24 is attached device 20, which can be an implantable infusion pump. While two distal ends are shown, the present invention can have one or more than two distal ends.

As further shown in the embodiment depicted in Figure 2, catheter 22 has a catheter portion 10 downstream of device 20 and upstream of connector 50.

Combined Diffuser/Restrictor

As shown in Figure 3A, where there is only one distal end 26, and there is no connector 50. Catheter portion 10 preferably comprises an elongated tubular wall 30 defining a central lumen 32. In this embodiment, catheter 22 begins at proximal end 24 and terminates at distal end 26. In this embodiment, distal end 26 has a catheter tip 34. Proximal end 24 defines an opening 17. Lumen 32 is defined by tubular wall 30. Tubular wall 30 terminates at end 36. In this embodiment, catheter tip 34 is attached to tubular wall 30. Catheter tip 34 has a lumen 38 to receive a drug from lumen 32, which can receive a drug pumped from device 20. Tubular portion 30 ends at end 36. Throughout this disclosure, the length of the portion of catheter tip 34 that is exposed to patient tissue is represented by a distance Ax@.

In this embodiment, catheter 22 of the present invention comprises a rigid assembly having a rigid tubular wall 30 for positioning the distal end 26 of the catheter 22 near a targeted patient site, the distal end 26 having a rigid porous portion or drug delivery segment 60 made of a sintered microsphere material having a porosity less than 0.50 microns for achieving homogenous delivery to the targeted patient site. In this embodiment, rigid porous drug delivery segment 60 comprises sintered metal microspheres to provide uniform porosity. Thus, a drug can be pumped from device 20, through opening 17, through lumen 32, through lumen 38, and through porous drug delivery segment 60 to a targeted patient site. In the embodiment shown in Figure 3A, delivery segment 60 can also be referred to as a combination diffuser and restrictor. In other words, delivery segment 60 restricts flow of a fluid containing a therapeutic drug and also diffuses that fluid so that the fluid is distributed to and emitted from the outer surface of delivery segment 60 that is exposed to a targeted patient site.

In this embodiment, the sintered metal powder of the delivery segment 60 defines multiple pores or porous openings 25. Preferably, the sintered metal powder is made of any light-weight, high tensile strength material, e.g., tungsten, titanium or tantalum.

The sintered rigid metal assemblies can be fabricated using a single cavity carbon mold, and a mold insert. Alternatively, the rigid metal assembly can be pressed into a green part using high pressure and sintered using heat to convert the green part to a fused structure (i.e., without carbon molds). Microspheres can be compressed together in each mold with pyrogenic processing.

When it is desired for the sintered metal powder to be radiopaque, a radiopaque material can be used, such as tungsten, titanium or tantalum. These metals are non-magnetic, and therefore are safe within a magnetic imaging environment.

The desired porosity of the sintered porous tip can be selected upon the diameter of the metal powder spheres used in the mold fabrication process. In this embodiment, the maximal dimensional distance between adjacent microspheres (i.e., pore size) is directly related to microsphere diameter, and is preferably as follows:

<u>Mircosphere Diameter Size)</u>	<u>Maximal Dimensional Distance (i.e. Pore Size)</u>
40 microns	Less than 6.2 microns
30 microns	Less than 4.7 microns
20 microns	Less than 3.1 microns
10 microns	Less than 1.6 microns
5 microns	Less than 0.8 microns
3 microns	Less than 0.5 microns
2 microns	Less than 0.3 microns

In actual practice, the maximal dimensional space is less than ideal since compression during the sintering process reduces dimension.

In U.S. Patent No. 5,846,220 (assigned to Medtronic), which is incorporated herein by reference, a therapeutic method for treatment of Alzheimer=s disease is disclosed. In U.S. Patent No. 5,846,220, the distal end has a porous tip or a closed end, wherein the catheter tip is preferably composed of porous material such as polysulfone hollow fiber, manufactured by Amicon, although polyethylene, polyamides, polypropylene and expanded

polytetrafluoroethylene (ePTFE) are also suitable, and is preferable porous along its entire length to enable indomethacin to flow into the hippocampus, and the preferred pore size is approximately ranged between 0.1-0.2 microns. See Col. 5, line 64 through Col. 6, line 4 of U.S. Patent No. 5,846,220.

5 The present invention differs from U.S. Patent No. 5,846,220, because, among other things, the present invention has much larger pore sizes, i.e., about 0.3 to 6.2 microns, and the porous material in the present invention is preferably made from sintered metal microspheres.

10 Another embodiment is shown in Figure 3B. This embodiment is similar to Figure 3A, except that there is a side opening 29 defined in distal end 26, and delivery segment 60 is positioned at side opening 29. Alternatively, delivery segment 60 can be positioned over or under side opening 29, relative to tubular wall 30. Side opening 29 can be incorporated into other embodiments shown and/or described herein.

15 Another embodiment is shown in Figure 3C. Figure 3C is similar to Figure 3A, except there are two distal ends, 26 and 26', two drug delivery segments 60, and two legs 80 and 80' connected to a connector 50 and corresponding distal ends 26 and 26'. This embodiment can be referred to as a catheter having two diffuser/restrictor catheter segments. This embodiment can be used to deliver a drug to two targeted patient sites.

20 An alternative embodiment is shown in Figure 3D. This embodiment is the same as that shown in Figure 3C, except that there are more than one connector 50, and more than two distal ends (in this embodiment, two distal ends 26 and two distal ends 26', for a total of four distal ends), more than two delivery segment portions 60, more than one catheter portion 10, and more than two distal tips 34 having lumens 38 to receive a drug from lumens 32. While four distal ends are shown, the present invention can have any number of distal ends as may be desired for drug delivery to targeted patient sites. Connectors 50 are used to connect the proximal end 24 to catheter portions 10 and catheter portions 10 to legs 80 and 80'. This embodiment can be referred to as catheter having multiple diffuser/restrictor catheter segments. This embodiment can be used to deliver a drug to more than two patient sites.

Separate Diffuser and Restrictor

Another embodiment of the present invention is shown in Figure 4A. This embodiment has many of the same elements previously described for other embodiments, and in particular, the embodiment shown in Figure 3C. The embodiment shown in Figure 4A has a catheter 22 having at least two distal ends 26 and 26', and catheter portion or leg 10 joined to each distal end with a connector 50. Further, restrictors 70 and 70' are placed in each legs 80 and 80', which are downstream of connector 50. Restrictors 70 and 70' can be made of any suitable material, including but not limited to, e.g. sintered metal powder, which is previously described above, or a material that provides a small diameter fluid path or capillary tubes. In this embodiment, the drug delivery segment (i.e., diffuser) 60 and restrictors 70 and 71' are separated from each other. The drug delivery segment 60 is at tip 34 of each of the distal ends 26 and 26', and the restrictors 70 and 71' are upstream of distal ends 26 and 26', respectively. This construction is particularly useful for delivery of drugs via multiple (more than one) catheter ends. For example, drug delivery to the two different hemispheres of the brain may be desired, and the present invention can deliver drugs to each hemisphere substantially equally because of the restrictors upstream of the distal ends, rather than at the distal ends as are the diffusers. In this embodiment of the present invention the following benefits are obtained by separating the diffuser and the restrictor: (1) increase in design options for the catheter tip; (2) improved reliability of catheter tip that is implanted in the brain tissue; and (3) reduced need to test the structure of the restrictor for biocompatibility.

An alternative embodiment is shown in Figure 4B. This embodiment is the same as that shown in Figure 4A, except that there is more than one connector 50, more than two distal ends (in this embodiment, two distal ends 26, and two distal ends 26' for a total of four distal ends), more than two delivery segment portions 60, more than one catheter portion 10, more than one leg 80, more than one leg 80', and more than two distal tips 34 having a lumen 38 to receive a drug from lumen 32. The connectors 50 are used to connect catheter portions 10 to the proximal end 24. This embodiment can be used to deliver a drug to more than two targeted patient sites.

Figure 5A shows the same structure as Figure 4A, except that in this other embodiment of the present invention, a restrictor 90 is placed upstream of connector 50 as well, so that there is a

restrictor in legs 80, 80' and catheter portion 10 of the catheter 22 joined by connector 50. This construction provides additional benefits. For example, having the restrictor 90 upstream of the connector 50 acts as a pre-filter, and thus removes any particulates prior to connector 50. This pre-filter function reduces particulates to the restrictors 70 and 70' downstream of connector 50, thus reducing the potential for different pressure drops and flow rates through the restrictors 70 and 70' downstream of connector 50, and ultimately the flow rate of the delivered drug through the diffusers or delivery segments 60 at the distal ends. In addition, this embodiment eliminates the possibility for incorrect insertion of a catheter where only one restrictor is downstream of connector, and one restrictor is upstream of connector 50, and one leg 80 or 80' not having a restrictor.

Figure 5B shows the same structure as Figure 4B, except that in this other embodiment of the present invention, a restrictor 90 is placed between proximal end 24 and the first connector 50 downstream of proximal end 24, to deliver a drug to more than two targeted patient sites.

In accordance with the embodiments shown in Figures 4A, 4B, 5A, and 5B, the drug fluid is pushing through many small pores of the drug delivery segment 60, and restrictors 70, 70' and 90 are of substantially equal flow resistance, and thus the delivered drug fluid follows a tortuous path. In these embodiments, the sum of the resistance to flow through multiple catheter distal ends is preferably equal so that equal flow is through the multiple catheter distal ends is obtained.

The structures described above and shown in Figures 4A, 4B, 5A, and 5B provide substantially equal flow through multiple catheter distal ends. Further discussion about the drug delivery segment (i.e. diffuser) and the fluid restrictor is set forth below.

Fluid Diffuser -- Fluid modeling reveals that distribution of fluid flow will occur with multiple small holes in simple silicone or polyurethane catheters. The diffuser, i.e., the drug delivery segment 60 shown in Figures 4A, 4B, 5A and 5B, can comprise any suitable structure. For example, the diffuser can comprise material having laser drilled holes having 0.001-0.005 inches diameter, and about 20-100 holes per diffuser. In one embodiment, the most distal of forty holes having 0.005 inches in diameter should have 76% of the flow compared to the most proximal hole (total flow 1 microliters/minute). For holes that are 0.001 inches in diameter, the distal hole should have 99.95% of the flow compared to the proximal hole. In addition, many

porous materials such as sintered metal, sintered polyethylene, or porous PTFE (i.e., Teflon) have diffuser capability. Thus, these structures are good diffusers at flow rates of about 1 microliter/minute to about 20 microliters/minute. For the diffuser material, a permeability constant of less than about 30,000 and a bubble point of less than about 10 psi is preferred.

5 Fluid Restrictor -- To balance the flow into each hemisphere of the patient=s brain, resistance to fluid flow in each leg of the catheter must be significant compared to the resistance at the tissue interface. If the restrictor creates a pressure drop of about 2-10 psi for a flow rate of about 10 microliters/minute, variation in interstitial pressure (less than 0.5 psi) will not create an imbalance of flow in the two catheter legs for a desired flow rate of about 1-10 microliters/minute. For this pressure drop, the material for the restrictor must be very tortuous 10 and have a significant length (i.e., thickness). For the restrictor material, a permeability constant of less than about 5,000 and a bubble point of less than about 10 psi is preferred. Since the restrictor is separated from the diffuser in this embodiment, the dimensions and materials are not limited to those typically considered acceptable for intraparenchymal implant. Acceptable 15 materials for restrictors given the larger lengths possible outside the brain are sintered porous metals, and sintered and/or porous polymers. Methods of manufacture and materials for the restrictors of the present invention include, but are not limited to, thin sheet filter (e.g., polyethersulfone or polypropylene, from Pall Corporation (East Hills, NY)), polycarbonate membrane (from Osmonics, Inc. (Minnetonka, MN)), polyvinylidene fluoride from Millipore Corporation (Bedford, MA)), depth filters from sintered metal (from Mott, Inc. (Farmington, CT)), sintered polyethylene (from Porex Surgical (College Park)), sintered glass (from Robu Glasfilter-Gerate GmbH (Hattert, Germany)), orifice sapphire, and/or capillary tubes. Preferably, the restrictor is a depth filter since it does not have disadvantages that the other materials may have. Sheet membranes have a disadvantage in that they have very small pores that may be prone 20 to clogging and require a high pressure to pass air through the wet membrane (i.e., bubble point). Orifice-type restrictors have the disadvantage of pressure drop that is extremely sensitive to diameter, thereby making it difficult and expensive to match two restrictors of this type to achieve substantially equal flow.

25

The restrictor should provide a large pressure drop. The pressure drop can be expressed by Darcy's Law. Darcy's Law is as follows:

$$K = \frac{-F \square T}{A \Delta P}$$

5

where K = permeability constant

F = flow rate

\square = viscosity for the fluid

T = thickness of porous path

10

A = surface area

ΔP = pressure delta

The conflicting requirements of the large surface area for a diffuser and a large pressure drop for the restrictor can be met by having separate structure for each of these functions.

15

Separating the restrictors from the diffusers, and placing the restrictors up stream of the diffusers results in the resistance to flow at the distal ends to be insignificant to the overall resistance to flow, and the fluid flow through multiple catheters is substantially equal.

20

An example is that for a AY@ catheter, if the resistance to flow through a first diffuser has a relative value of 1, and the resistance to flow through a second diffuser has a relative value of 2, then twice as much flow will go through the first diffuser.

25

On the other hand, if restrictors with a relative resistance value of 100 are placed up stream of the first and second diffusers, so that the overall resistance to flow through the first diffuser has a relative value of 101, and the overall resistance to flow through a second diffuser has a relative value of 102, then the flow through the first and second diffusers will be substantially equal. Equal restriction of fluid flow through each leg is the key to substantially equal fluid flow through each leg.

The features provided by this embodiment include:

1. Separate diffuser and restrictor features for bilateral intraparenchymal drug delivery catheter.

2. Use of simple diffusers that have insufficient tortuosity of the porous structure to make acceptable restrictors.
3. Use of multiple small holes (less than 0.005 inches in diameter; created with a laser) as a fluid diffuser.
5. Location of catheter restrictor at proximal end (not distal) of catheter to provide greater device flexibility, i.e., reduce the number of joint, bonds, components for distal catheter segment.
4. Capability to control flow in the brain catheter with changes in catheter design/materials not directly implanted in the brain tissues.

10 Thus, the present invention provides for multiple catheter ends for drug delivery. More specifically, the present invention provides for multiple catheter ends, e.g. at least two, into the brain of patient, and even more specifically, into the two different hemispheres of the brain, with each catheter end supplied with therapeutic drugs by the same pump, and with the fluid flow of the therapeutic agent being substantially equal between the two catheter ends.

15 The present invention also provides a catheter to diffuse a therapeutic agent over a large surface area than from a single point source. The benefits of this structure is that it decreases the fluid flux and reduces the change of damaging patient tissue. In order for equal or near equal bilateral drug delivery to occur, two catheters are required. It is usually desirable to have equal flow in both catheters to deliver equal amounts of drug to both brain hemispheres.

20 The present invention can be used for many drug delivery applications, including but not limited to intraparenchymal tissue delivery, intrathecal drug delivery, and intra-cerebral ventricular (ICV) drug delivery.

25 Many modifications and variations may be made in the techniques and structures described and illustrated herein without departing from the spirit and scope of the present invention. For example, the present invention can be used to infuse a cytostatic agent into a malignant mass located in a variety of places in the body, or infuse a nerve growth factor into the intrathecal space of the spinal column, or to treat Alzheimer=s disease by infusing indomethacin or other drug into a patient=s hippocampus. Accordingly, the techniques and structures described

and illustrated herein should be understood to be illustrative only and not limiting upon the scope of the present invention.

WE CLAIM:

1. A medical catheter comprising:

a proximal end having an opening for fluid containing a therapeutic drug,
5 a distal end, the distal end defining at least one opening, and
a porous portion covering the opening defined by the distal end.

2. The medical catheter of claim 1 wherein the opening defined by the distal end is a side opening.

10 3. The medical catheter of claim 1 wherein the porous portion defines pores ranging in diameter size from about 0.3 to 6.2 microns.

15 4. The medical catheter of claim 1 wherein the porous portion comprises sintered metal microspheres.

5. The medical catheter of claim 1 wherein the porous portion comprises a radiopaque material.

20 6. The medical catheter of claim 1 wherein the porous portion comprises tungsten, tantalum, or titanium.

7. The medical catheter of Claim 1 wherein the porous portion restricts and diffuses fluid through the opening defined by the distal end.

25 8. A medical catheter comprising:

a proximal end having an opening for fluid containing a therapeutic drug,

at least two distal ends, the proximal end connected to the distal ends with a branched connector, the distal ends each defining at least one opening,

a diffuser covering the opening of each distal end, and

a restrictor between the branched connector and each distal end to provide substantially equal flow through each distal end.

5 9. The medical catheter of claim 8 wherein the opening defined by at least one distal end is a side opening.

10 10. The medical catheter of claim 8 further having a restrictor upstream of the connector.

11. The medical catheter of claim 8 wherein the diffusers define pores ranging in diameter size from about 0.3 to 6.2 microns.

12. The medical catheter of claim 8 wherein at least one diffuser comprises a radiopaque material.

15 13. The medical catheter of claim 8 wherein the diffusers comprise a sintered metal microsphere portion.

20 14. The medical catheter of claim 8 wherein the diffusers comprise tungsten, tantalum, or titanium.

25 15. The medical catheter of claim 8 wherein each restrictor comprises material defining pores ranging in diameter size from about 0.3 to 6.2 microns.

16. The medical catheter of claim 8 wherein each restrictor comprises a radiopaque material.

17. The medical catheter of claim 8 wherein a least one restrictor comprises tungsten, tantalum, or titanium.

18. The medical catheter of claim 10 wherein the restrictor upstream of the connector comprises material defines pores ranging in diameter size from about 0.3 to 6.2 microns.

5 19. The medical catheter of claim 10 wherein the restrictor upstream of the connector comprises a radiopaque material.

20. The medical catheter of claim 10 wherein the restrictor upstream of the connector comprises tungsten, tantalum, or titanium.

1 / 12




FIG. I

SUBSTITUTE SHEET (RULE 26)

2/12




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3 / 12




FIG. 3A

SUBSTITUTE SHEET (RULE 26)

4 / 12





FIG. 3B

SUBSTITUTE SHEET (RULE 26)

5 / 12



SUBSTITUTE SHEET (RULE 26)

6 / 12




FIG. 3D

SUBSTITUTE SHEET (RULE 26)

7/12





FIG. 4A

SUBSTITUTE SHEET (RULE 26)

8/12



SUBSTITUTE SHEET (RULE 26)

9 / 12




FIG. 5A

SUBSTITUTE SHEET (RULE 26)

10/12




FIG. 5B

SUBSTITUTE SHEET (RULE 26)

11/12




FIG. 6

12/12




FIG. 7

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07810 A3

(51) International Patent Classification⁷: **A61M 25/00.**
5/142

MN 55128 (US). MORRIS, Mary, M.: 2917 Woodale Drive, Mounds View, MN 55112 (US). HANKNER, Douglas, O.: 1482 North Innsbruck, Fridley, MN 55432 (US). HAMLEN, Robert, C.: 6820 Woodale Avenue South, Edina, MN 55435 (US).

(21) International Application Number: **PCT/US01/23434**

(22) International Filing Date: 26 July 2001 (26.07.2001)

(25) Filing Language: English

(74) Agents: WALDKOETTER, Eric, R. et al.: Medtronic, Inc., LC340, 710 Medtronic Parkway, Minneapolis, MN 55432 (US).

(26) Publication Language: English

(81) Designated States (national): AU. CA.

(30) Priority Data:
09/625,751 26 July 2000 (26.07.2000) US

(84) Designated States (regional): European patent (AT. BE. CH. CY. DE. DK. ES. FI. FR. GB. GR. IE. IT. LU. MC. NL. PT. SE. TR).


(71) Applicant: MEDTRONIC, INC. [US/US]: 710 Medtronic Parkway Northeast, Minneapolis, MN 55432 (US).

(72) Inventors: ELSBERRY, Dennis, D.; 5345 Union Terrace Lane North, Plymouth, MN 55442 (US). CHRISTIANSEN, Chris; 4641 Hillvale Circle North, Oakdale,

Published:
— with international search report

[Continued on next page]

(54) Title: CATHETER FOR TARGET SPECIFIC DRUG DELIVERY



(57) Abstract: A medical catheter (22) comprising a proximal end (24) having an opening for fluid containing a therapeutic drug, a distal end (26), the distal end defining at least one opening, and a porous portion covering the opening defined by the distal end. In one embodiment, the medical catheter comprises a proximal end having an opening for fluid containing a therapeutic drug, at least two distal ends (26, 26'), the proximal end connected to the two distal ends with a connector (50), the distal ends each defining at least one opening, a diffuser covering the opening of each distal end, and a separate restrictor downstream of the connector and upstream of each distal end to provide substantially equal flow through each distal end. An additional restrictor can also be placed upstream of the connector. In another embodiment, a combination diffuser and restrictor covers the opening of each distal end.

WO 02/07810 A3



(88) Date of publication of the international search report:

13 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23434

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61M25/00 A61M5/142

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 186 745 A (LEWIS DAVID W ET AL) 5 February 1980 (1980-02-05) the whole document	1-3, 7
A	---	8, 9, 11, 15, 18
X	US 6 093 180 A (ELSBERRY DENNIS D) 25 July 2000 (2000-07-25) abstract; figures 3,4 column 3, line 11 -column 5, line 22	1, 5, 7
A	---	6, 12, 14, 16, 17, 19, 20
X	US 3 817 248 A (BUCKLES R ET AL) 18 June 1974 (1974-06-18) column 5, line 13 -column 6, line 4; figures 1,2	1, 7
A	---	4, 8
	-/-	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

10 January 2002

21/01/2002

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Jameson, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23434

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 015, no. 177 (C-0829), 7 May 1991 (1991-05-07) & JP 03 041967 A (OLYMPUS OPTICAL CO LTD), 22 February 1991 (1991-02-22) abstract; figures 1-7 ----	1,7
A		8
X	EP 0 564 321 A (CELSA L G SA) 6 October 1993 (1993-10-06) the whole document ----	8
A	US 3 469 578 A (BIERMAN HOWARD R) 30 September 1969 (1969-09-30) column 9, line 35-57; figure 6 abstract	4
A	WO 98 15315 A (ONCOCATH INC) 16 April 1998 (1998-04-16) abstract; figures 1,3 -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No PCT/US 01/23434	
---	--

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 4186745	A 05-02-1980	NONE			
US 6093180	A 25-07-2000	US 2001027599 A1			11-10-2001
		AU 5545596 A			18-11-1996
		WO 9633761 A1			31-10-1996
US 3817248	A 18-06-1974	NONE			
JP 03041967	A 22-02-1991	NONE			
EP 0564321	A 06-10-1993	FR 2689403 A1			08-10-1993
		DE 69306292 D1			16-01-1997
		DE 69306292 T2			03-04-1997
		EP 0564321 A2			06-10-1993
US 3469578	A 30-09-1969	NONE			
WO 9815315	A 16-04-1998	US 5931774 A			03-08-1999
		AU 4751497 A			05-05-1998
		EP 0934094 A1			11-08-1999
		JP 2001504004 T			27-03-2001
		WO 9815315 A1			16-04-1998

THIS PAGE BLANK (USPTO)